 |
|
Mesothelioma: A Killer
Lurks in the Lungs |
|
 |
Gene Therapy Studied for Alzheimer's |
|
September 24, 2004 11:03:11 AM PDT , HealthDay |
|
FRIDAY, Sept. 24 (HealthDayNews) -- The use of gene therapy to deliver nerve growth factor into areas of the brain where neurons are degenerating, to reverse the ravages of Alzheimer's disease, is being investigated by Rush University Medical Center scientists.
If this technique proves successful, it could be a major step forward in finding a way to slow the course of Alzheimer's disease.
This approach uses the gene therapy agent CERE-110 to carry the nerve growth factor (NGF) gene. It codes for the NGF protein, which has a positive effect on brain cells, the researchers said.
One of the Rush scientists' key objectives is to deliver CERE-110 and its NGF cargo directly to the basal forebrain, the brain region that's almost always affected by Alzheimer's disease. The scientists don't want CERE-110 to travel to other parts of the brain, where it may cause side effects, they said.
The Chicago-based Rush team has started a two-year Phase I study to evaluate the safety and tolerability of two different doses of CERE-110. The study will include six to 12 people with mild to moderate Alzheimer's disease.
The study is being funded by Ceregene Inc., of San Diego, the developer and manufacturer of CERE-110.
More information
The U.S. National Institute on Aging has more about Alzheimer's disease. |
US reviewer says pressured in antidepressant probe
Last Updated: 2004-09-23 16:34:06 -0400 (Reuters Health)
By Lisa Richwine
WASHINGTON (Reuters) - A U.S. government medical reviewer who raised concerns about antidepressant use by children said on Thursday he was pressured to hide information and submit an altered document to congressional investigators.
Dr. Andrew Mosholder, a Food and Drug Administration epidemiologist, said agency officials did not want lawmakers to know the agency was conducting an internal probe of whether he leaked his concerns about antidepressant risks to a reporter.
Mosholder concluded last year that children and teens who took antidepressants during clinical trials were more likely to report suicidal thoughts or actions. His superiors disagreed and prevented him from presenting his findings at a public meeting last February.
The Senate Finance Committee began investigating. Mosholder wanted to give the panel an affidavit drawn up for the FDA probe in which he said he did not leak the information.
In testimony before the House Energy and Commerce Committee on Thursday, Mosholder said FDA officials told him to remove a reference to the agency's probe, as well as some names to protect privacy.
"Had Dr. Mosholder not acted to thwart the submission of an altered document to a bona fide congressional investigation, a criminal act of obstruction of justice would have occurred," charged Rep. Peter Deutsch, a Florida Democrat.
Mosholder said FDA officials told him not to tell congressional investigators the document had been changed.
In a May 4 e-mail to Mosholder an official in the FDA chief counsel's office wrote, "I don't think that it's necessary to indicate that this document represents a version of the earlier one by noting things have been omitted. That simply invites the committee to ask further questions about what was in the earlier version."
Mosholder said that made him uncomfortable and he eventually provided the committee his original document minus the names.
The FDA has been accused of trying to conceal information throughout the antidepressant controversy. Despite Mosholder's findings months ago, top officials did not confirm a link between antidepressants and suicidal behavior in youth until last week.
Dr. Robert Temple, director of the FDA's Office of Medical Policy, defended the agency's actions. He said data were unclear and officials wanted to be certain of the risks before warning doctors and the public.
"The agency realizes its responsibility to the public to find the right answer to this question," Temple said at the hearing.
For some patients, the drugs can be life-saving by relieving depression, a serious mental illness that itself raises the risk of suicide.
Lawmakers at the hearing said one FDA medical reviewer raised the question of whether Pfizer Inc.'s Zoloft might increase the risk of suicidal behavior in pediatric patients in 1996.
The FDA now is drafting new warnings for all antidepressants about the possibility of suicidal thoughts and actions among youth who take the drugs. A panel of outside experts has recommended the drug labels highlight the risk in a "black box," the strongest warning for prescription drugs.
An FDA analysis estimated 2 percent to 3 percent of children and teens who take antidepressants might have an elevated risk for suicidal behavior. But no suicides occurred in studies of more than 4,000 children as young as six.
Antidepressants include Eli Lilly and Co.'s Prozac, Pfizer's Zoloft, GlaxoSmithKline Plc's Paxil, Forest Laboratories Inc.'s Celexa and Wyeth's Effexor. Prozac also is sold under the generic name fluoxetine.
Copyright © 2004 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
Continue with:
|
